Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJune 27, 2017	Minerva Neurosciences, Inc. to Offer Common Shares WALTHAM, Mass. , June 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 5,000,000 shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to be sold by Minerva.	View HTML Minerva Neurosciences, Inc. to Offer Common Shares 19.8 KB
Toggle SummaryMay 15, 2017	Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101	View HTML Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101 91.4 KB
Toggle SummaryDecember 9, 2015	Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates Patient Enrollment Progress During 2015 Confirms Timeline Expectations for Topline Data Availability From Four Trials in First Half of 2016	View HTML Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates 24.1 KB
Toggle SummaryJune 1, 2020	REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia WALTHAM, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the company will hold a webcast on Friday, June 5, 2020	View HTML PDF Version

Press Releases

Shareholder Tools